Skip to main content
. 2015 Mar 23;33(15):1688–1696. doi: 10.1200/JCO.2014.58.0225

Table A2.

Unrelated Reported Adverse Events Within the First 6 Weeks of HER2-CAR T-Cell Infusion

Adverse Event Grade 1
Grade 2
Grade 3
Grade 4
No. of Patients % No. of Patients % No. of Patients % No. of Patients %
Hematologic toxicities
    Anemia 8 42.1 1 5.3
    Leukopenia 5 26.3 1 5.3
    Neutropenia 4 21.1 1 5.3
    Lymphopenia 5 26.3 1 5.3
Nonhematologic toxicities
    General
        Anxiety 1 5.3
        Fatigue 3 15.8
        Fever 1 5.3
        Hot flashes 2 10.5
        Flu-like symptoms 1 5.3
        Muscle weakness 1 5.3 1 5.3
    HEENT
        Watery eye 1 5.3
        Rhinorrhea 2 10.5
    GI
        Dry mouth 1 5.3
        Nausea/vomiting 5 26.3 1 5.3
        Diarrhea 1 5.3
        Constipation 1 5.3
    Cardiac
        Hypotension 1 5.3
        Paroxysmal tachycardia 1 5.3
    Respiratory
        Cough 5 26.3
        Upper respiratory tract infection 1 5.3
        Wheezing 1 5.3
    Pain
        Abdominal 2 10.5
        Back 2 10.5 1 5.3
        Bone 1 5.3
        Chest 1 5.3
        Extremity 1 5.3
        Neck 1 5.3
        Pain NOS 2 10.5
        Throat 1 5.3
        Tumor site 1 5.3 1 5.3
    CNS
        Headache 2 10.5
        Intracranial hemorrhage 1 5.3
        Seizure 2 10.5
        Numbness 1 5.3
    Musculoskeletal
        Bruising 1 5.3
        Ankle fracture 1 5.3
    Laboratory
        ALT 3 15.8
        Alkaline phosphatase 3 15.8 2 10.5
        AST 6 31.6
        Hyperglycemia 2 10.5
        Hyperkalemia 1 5.3 1 5.3
        Hypernatremia 2 10.5
        Hypoalbuminemia 1 5.3
        Hypocalcemia 2 10.5
        Hypokalemia 5 26.3
        Hyponatremia 3 15.8

Abbreviations: CAR, chimeric antigen receptor; HEENT, head, eyes, ears, nose, and throat; HER2, human epidermal growth factor receptor 2; NOS, not otherwise specified.